Informed Consent
Item
written informed consent obtained prior to the initiation of study procedures.
boolean
C0021430 (UMLS CUI [1])
Gender | Age
Item
men ≥ 18 years of age.
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Adenocarcinoma of prostate
Item
histologically documented prostatic adenocarcinoma.
boolean
C0007112 (UMLS CUI [1])
Castration-resistant prostate cancer
Item
history of castration-resistant prostate cancer.
boolean
C1328504 (UMLS CUI [1])
TNM clinical staging
Item
known m1 disease.
boolean
C3258246 (UMLS CUI [1])
Imaging study Secondary malignant neoplasm of prostate
Item
undergone imaging study for metastatic prostate cancer ≤ 3 months.
boolean
C1881134 (UMLS CUI [1,1])
C0347001 (UMLS CUI [1,2])
ECOG performance status
Item
ecog performance status ≥ 3.
boolean
C1520224 (UMLS CUI [1])
Pleural Effusion, Malignant | Ascites
Item
known malignant pleural effusions or ascites.
boolean
C0080032 (UMLS CUI [1])
C0003962 (UMLS CUI [2])
Investigational Therapy Castration-resistant prostate cancer TNM clinical staging | Taxotere | docetaxel | Provenge | sipuleucel-T | Zytiga | abiraterone acetate | Xtandi | enzalutamide | Jevtana | cabazitaxel | Xofigo | Radium Ra-223 dichloride
Item
current or prior treatment with investigational therapy for m0 castration-resistant prostate cancer (taxotere (docetaxel), provenge® (sipuleucel-t), zytiga (abiraterone acetate), xtandi (enzalutamide), jevtana (cabazitaxel), or xofigo (radium ra 223 dichloride).
boolean
C0949266 (UMLS CUI [1,1])
C1328504 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,3])
C0699967 (UMLS CUI [2])
C0246415 (UMLS CUI [3])
C1135133 (UMLS CUI [4])
C1706668 (UMLS CUI [5])
C3153774 (UMLS CUI [6])
C2607886 (UMLS CUI [7])
C3496799 (UMLS CUI [8])
C3496793 (UMLS CUI [9])
C2927159 (UMLS CUI [10])
C2830183 (UMLS CUI [11])
C3643595 (UMLS CUI [12])
C3541342 (UMLS CUI [13])